The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
The in-vitro activity of the new 5-methylated fluoroquinolone OPC-17116 was compared with that of other fluoroquinolines and beta-lactams against a total of 690 bacterial strains. With the exception of Klebsiella and Serratia spp., 90% of the Enterobacteriaceae were inhibited by 0.25 mg/L. OPC-17116 inhibited 90% of Serratia spp. at 8 mg/L and Klebsiella spp. at 4 mg/L. Moraxella catarrhalis and Haemophilus influenzae were highly susceptible (MIC90 < or = 0.03 mg/L). Pseudomonas aeruginosa were more susceptible to ciprofloxacin (MIC90 0.25 mg/L) than OPC-17116 (MIC90 1 mg/L). Generally, OPC-17116 was more active than ciprofloxacin against Gram-positive cocci, 90% of Staphylococcus spp. being inhibited by < or = 0.25 mg/L. OPC-17116 displayed greater activity than ciprofloxacin against Chlamydia spp. (MICs < or = 0.12 and < or = 2 mg/L, respectively).
Wise
R
R
Department of Microbiology, Dudley Road Hospital, Birmingham, UK.
Andrews
J M
JM
Brenwald
N
N
D000658:Amoxicillin / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001441:Bacteroides fragilis / Q000187:drug effects; D002433:Cefaclor / Q000494:pharmacology; D002692:Chlamydia trachomatis / Q000187:drug effects; D016993:Chlamydophila pneumoniae / Q000187:drug effects; D002939:Ciprofloxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000494:pharmacology; D010879:Piperazines / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding; D015363:Quinolones / Q000378:metabolism / Q000494:pharmacology*; D013210:Staphylococcus / Q000187:drug effects
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; D002939:Ciprofloxacin; D002433:Cefaclor; D000658:Amoxicillin; C075375:grepafloxacin; D009643:Norfloxacin